Depression - Articles - Page 14

Inflammation and Depression: An Interview with Andrew Miller, MD

February 10, 2020

30-50% of patients with depression have signs of inflammation, and some of those markers may help predict which medication they'll respond to. Andrew Miller, MD, of Emory University is one of the leading researchers in this field, and in this interview he tells us when to suspect inflammation and how...

Getting Uncomfortable with Esketamine

January 13, 2020

Nolan Williams, MD

Nolan Williams, MD

Director of the Brain Stimulation Lab and Interventional Psychiatry Clinical Research Program; Assistant Professor of Psychiatry at Stanford University, CA. Dr. Williams has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The FDA approval of esketamine (Spravalto) left some unanswered questions, including suicide, addiction, withdrawal, neurotoxicity, and bladder inflammation. Nolan Williams addresses those risks and looks at where esketamine fits among other options like TMS and ECT. Dr. Williams directs the Interventional Psychiatry Clinical Research Program and Brain Stimulation Lab at Stanford University.

Antipsychotic Maintenance: How Long is Enough?

January 13, 2020

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Atypical antipsychotics can work quickly in mood disorders, but their long-term risks give us pause. When is it safe to discontinue them? The answer, it turns out, depends on whether we look to industry-supported or industry-independent trials.

TMS: Deeper is not Better

January 13, 2020

Edmund S. Higgins, MD.

Edmund S. Higgins, MD. Dr. Higgins has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Two devices are available for transcranial magnetic stimulation (TMS). Neurostar came first with the figure-8 coil, which is now off-patent, while Brainsway’s H-coil which claims to reach deeper into the cerebral cortex. See how they compare in the first head-to-head controlled trial, undertaken without industry support.

Heart Rate Changes Linked to Emotional Dysregulation

November 21, 2019

Jess Levy, MD

Jess Levy, MD Dr. Levy has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Clinical psychiatry is becoming more attuned to the utility of tracking physiological markers of
regulation and dysregulation. The study clarifies where we are in understanding heart rate as a
clue in diagnosis and management.

A Practical Guide to Light Therapy

November 15, 2019

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Few natural therapies perform well when stacked head-to-head with medication. Light therapy is an exception. When used correctly, it can treat winter and non-winter depression and augment antidepressants. Learn which lightboxes work, how to use them, and a new light therapy protocol for bipolar depression.

Highlights From This Issue

October 3, 2019

Quick hits on what you’ll find in this issue.

Outpatient Management of Opioid Addiction

October 3, 2019

Sandra Gomez-Luna, MD

Sandra Gomez-Luna, MD

Child, adolescent, and adult psychiatrist in Darien, CT. Medical Director of Parent Child Support Center, a subsidiary of Behavioral Health Care (BHcare)

Dr. Gomez-Luna has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The opioid crisis demands that child psychiatrists understand more about outpatient treatment in adolescents as more of us are asked to participate in assessment and treatment planning for this population. In this QA, we discuss some of the well-laid-out approaches for child psychiatrists to manage opioid treatment within the child or teen’s community.

Assessing and Treating Cannabis Use Disorder

October 3, 2019

Gabriella Gobbi, MD, PhD

Gabriella Gobbi, MD, PhD

Professor, Department of Psychiatry, McGill University; Psychiatrist and Clinical Scientist at the McGill University Health Center

Dr. Gobbi has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Child psychiatrists are grappling with the problem of pervasive use of marijuana in an age where legalization of use for adults has led to even greater use in teens. In this QA, we discuss the impact of cannabis, its interaction with depression, and the conundrum of cannabis withdrawal so that child psychiatrists can gain tools for addressing marijuana use and addiction in their outpatient practice.

Anti-Inflammatories as Antidepressants?

October 3, 2019

Edmund S. Higgins, MD.

Edmund Higgins, MD Dr. Higgins has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A host of anti-inflammatory medicines are effective in treatment-resistant depression, particularly celecoxib.